BioWorld

Oct. 29, 2007

Kosan, Roche End Partnership; Epothilone Goes Back Home

Kosan Biosciences Inc. and Roche Holding AG ended their five-year collaboration to develop and commercialize epothilones, anticancer agents that inhibit cell division. (BioWorld Today) Read More

Biotech Allozyne Improving Protein Drugs With $30M Round

Jennerex Seeks Oncolytic Strait Between Scylla And Charybdis

Clinical Data IVD Asset Sale: $19.5M For Drug, Test Bids

NovaBay Prices IPO At $4/Share Gets $20M To Advance Pipeline

Other News To Note

Clinic Roundup

Earnings Roundup

AACR Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

Mechanism underlying so-called idiopathic autism inception unveiled

BioWorld Science

Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...